Use of receptor of a ror family for screening substances useful for the treatment of atherosclerosis
CA 2326141 C · Owner: Merck Patent Gesellschaft Mit Beschraenkter Haftung · Inventors: Bonhomme, Yves; Raspe, Eric
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The subject of the present invention is the use of the ROR receptors and/or of their response element or alternatively of a functional equivalent thereof for the screening of substances having antiatherosclerotic properties. The invention also relates to the methods of screening substances having antiatherosclerotic properties using the ROR receptors and/or their response elements. The invention also relates to the use of the methods of screening according to the present invention in order to characterize justify and claim , the mechanism of action of substances having antiatherosclerotic properties using the ROR receptors and/or their response elements as well as their effects on …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 24, 1999 and granted April 26, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended March 24, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 24, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.